Please try another search
For the fiscal year ended 31 December 2021, Acacia Pharma Group PLC revenues increased from $211K to $1.2M. Net loss increased 100% to $67.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Administrative Expenses increase from $11.6M to $31.1M (expense), Sales & Marketing Expenses increase of 65% to $32M (expense).
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 0.72 | 0.44 | 0.21 | 0 |
Gross Profit | 0.49 | 0.38 | 0.18 | |
Operating Income | -41.3 | -24.96 | -18.14 | -12.78 |
Net Income | -39.76 | -27.31 | -18.28 | -15.2 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 62.01 | 102.54 | 102.83 | 37.04 |
Total Liabilities | 36.15 | 36.97 | 42.35 | 11.32 |
Total Equity | 25.87 | 65.57 | 60.48 | 25.72 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | -44.57 | -19.93 | -25.36 | -11.94 |
Cash From Investing Activities | 0 | 0 | 0.04 | 0.04 |
Cash From Financing Activities | 20.69 | 22.4 | 55.99 | 19.38 |
Net Change in Cash | -25.08 | 0.44 | 29.68 | 7.6 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review